Systemic lupus erythematosus tests are most informative when blood, urine, symptoms, and examination findings are read together. ANA can raise a question about autoimmunity; anti-dsDNA and anti-Smith may add diagnostic support; complement, a complete blood count, kidney function, and urine findings help show how the body is affected. No single result establishes lupus or a flare.
This Ulta Lab Tests guide explains what these tests can contribute and how to discuss them with your clinician. It is educational and does not provide a diagnosis or a personal testing schedule. For the broader context, see our guide to inflammation and autoimmune blood tests.
SLE is an autoimmune disease in which immune activity can affect multiple tissues, including skin, joints, blood cells, kidneys, and other organs. Symptoms and severity vary, and periods of greater activity may alternate with more stable disease. Diagnosis requires a clinician to evaluate the overall pattern and consider other explanations. The National Institute of Arthritis and Musculoskeletal and Skin Diseases describes diagnosis as a combination of medical history, examination, and laboratory or other investigations.
A cluster of findings is generally more informative than a nonspecific symptom in isolation. Family history and demographic risk can add context, but neither determines who has lupus.
| Finding or context | Why a clinician may investigate | Important limitation |
|---|---|---|
| Persistent joint swelling, characteristic rashes, or mouth ulcers | May contribute to a multisystem autoimmune pattern | Other illnesses can produce similar findings. |
| Unexplained low blood counts | May indicate blood-cell involvement | Medication effects, infection, and nutritional deficiencies also matter. |
| Protein or blood in urine, swelling, or new hypertension | Raises concern about kidney involvement | Kidney disease can also be silent and can have causes other than lupus. |
| Fatigue or an incidental positive ANA | May prompt review of the broader history | Neither alone establishes SLE or justifies every autoimmune test. |
The ANA screen by immunofluorescence, with reflex to titer and pattern looks for antinuclear antibodies. A positive result may be reported with a titer and staining pattern. These details can help interpretation, but they do not identify a diagnosis by themselves.
ANA positivity can occur in people without autoimmune disease, with other autoimmune conditions, and in some medication or infection contexts. A negative result makes SLE less likely; persistent clinical concern still deserves appropriate assessment. MedlinePlus explains the uses and limitations of ANA testing.
The useful next question is: Does this result fit the clinical picture? A person with inflammatory joint findings and abnormal urine needs a different evaluation from someone with an incidental positive ANA and no suggestive symptoms. Classification criteria combine clinical and laboratory findings for consistent disease classification; they should not be used as a self-diagnosis checklist.
These tests supply complementary information. A clinician selects the relevant combination; this table is not a recommendation for everyone with fatigue or a positive ANA to order the entire list.
| Test | What it measures and why it matters | What an abnormal result may suggest | Main limitation |
|---|---|---|---|
| ANA | Antinuclear antibodies; supports an autoimmune evaluation | A positive result may fit SLE or another autoimmune condition | Positive results also occur without autoimmune disease; titers are not routine activity targets. |
| Anti-dsDNA | Antibodies to double-stranded DNA; can support SLE assessment | A rise may accompany greater activity in some patients | Methods differ; a normal result does not exclude SLE or nephritis. |
| Anti-Smith (Sm) | An antibody that can provide specific support for SLE | A positive result strengthens a compatible diagnostic pattern | Many patients are negative; serial measurement usually does not guide activity assessment. |
| Complement C3 and C4 | Levels of immune-system proteins | Falling levels may accompany immune-complex activity | Low levels are not specific, and normal levels do not exclude active disease. |
| CBC with differential and platelets | Red cells, white cells, platelets, and related measurements | Low hemoglobin, white cells, or platelets may need investigation | A CBC cannot identify the cause; high white cells may reflect infection, medication, or inflammation. |
| Comprehensive metabolic panel (CMP) | Includes creatinine, calculated eGFR, albumin, electrolytes, and liver tests | Rising creatinine, falling eGFR, or low albumin can add concern | Results have multiple causes; normal filtration does not exclude early protein leakage. |
| Complete urinalysis | Urine chemistry and microscopic findings | Protein, blood, or certain casts may signal kidney or urinary disease | Infection, menstruation, collection problems, and other causes must be considered. |
| Urine total protein-to-creatinine ratio | Quantifies protein relative to urine creatinine in a spot sample | An increased ratio indicates greater protein loss | An abnormal result does not establish lupus as the cause; collection and biological variation matter. |
For further explanation, see ARUP Consult’s guide to SLE laboratory evaluation and Hospital for Special Surgery’s guide to lupus blood tests, along with MedlinePlus resources on complement and the CBC.
The evaluation starts with the clinical question: suspected SLE, a new organ problem, a possible flare, or treatment monitoring. When lupus is a meaningful concern, assessment of blood cells and kidneys may occur at the same time as antibody testing. Kidney assessment should not wait for every antibody result.
Next, the clinician asks whether each abnormality fits lupus or needs another explanation. Infection, medication effects, another autoimmune disease, and common conditions can coexist with SLE. Additional tests should answer a specific unresolved question.
For example, SSA/Ro and SSB/La antibodies may be relevant to an overlapping clinical pattern or pregnancy planning; RNP antibody may help assess overlap features. ESR and CRP can supply inflammation context, but neither distinguishes a lupus flare from all other causes. Their results should not replace evaluation for infection when clinically indicated.
Antiphospholipid antibodies are relevant to clotting and pregnancy risk assessment in SLE. Their assessment is not restricted to people who have already had a clot or pregnancy complication; the 2025 ACR SLE guideline includes antiphospholipid antibody assessment within care for people with SLE.
The principal laboratory groups are lupus anticoagulant testing, anticardiolipin IgG and IgM antibodies, and anti-beta-2 glycoprotein I IgG and IgM antibodies. The linked beta-2 glycoprotein I antibody panel also includes IgA, which is not interchangeable with the core IgG/IgM tests used in APS assessment.
A positive antibody result alone does not establish antiphospholipid syndrome. Clinical history, persistence, and possible test interference matter. Anticoagulants can complicate lupus anticoagulant testing; medication instructions must come from the treating clinician. Our guide to antiphospholipid syndrome tests explains that separate diagnostic question.
Discordant results are a reason to investigate context, not to disregard the finding that does not fit. The following examples are hypothetical and are not diagnoses.
| Example pattern | What it may mean | Useful clinical follow-up |
|---|---|---|
| Positive ANA with no specific symptoms and otherwise reassuring findings | The result may be incidental | Review why the test was ordered before expanding testing. |
| Compatible symptoms with anti-dsDNA or anti-Smith positivity | The combined pattern increases concern for SLE | Assess the full clinical picture and affected organs. |
| New proteinuria despite stable anti-dsDNA and normal complement | Kidney disease remains possible | Evaluate urine findings and kidney function promptly; consider other causes. |
| Fatigue, low hemoglobin, and ferritin of 9 ng/mL | Iron depletion may contribute to symptoms | Investigate iron deficiency and its cause instead of assuming a lupus flare. |
| Improving urine protein and stable kidney function while anti-dsDNA remains high | Clinical and antibody trends may improve at different rates | Review all findings before deciding whether treatment response is adequate. |
The ferritin example illustrates targeted investigation: ferritin testing assesses iron stores, and low ferritin may indicate iron deficiency. It is not a recommendation to add nutritional testing to every lupus evaluation.
Lupus nephritis is kidney inflammation associated with SLE. It may develop with few noticeable symptoms. Blood testing assesses filtration, while urinalysis and quantitative protein testing can identify abnormalities that a normal creatinine result does not reveal. The NIDDK lupus nephritis resource explains why urine and blood tests are both important.
The ACR lupus nephritis recommendations call for proteinuria screening at least every 6–12 months in SLE without known kidney disease, and during flares affecting other organs. New abnormal results or symptoms can require earlier assessment. Established nephritis needs a more individualized monitoring plan.
For a broader explanation of filtration and urine measurements, see our kidney function testing guide. Kidney results should be shared with the treating team even when antibody results look reassuring.
Follow-up considers symptoms, examination, organ findings, treatment effects, and selected laboratory trends. ANA does not need to become negative for someone to improve. Anti-Smith generally contributes more to diagnosis than repeated activity assessment. Anti-dsDNA and complement can be helpful in context, particularly when previous changes have tracked a person’s disease.
A useful record includes the date, laboratory method, units, symptoms, medication changes, and the clinician’s interpretation. A monitoring interval is a planned review point; it is not a reason to wait when something new develops.
Use the reference interval and units on the actual report. ANA titers, antibody assays, and laboratory cutoffs differ. Small changes across different methods may not represent a biological change. When feasible, compare results obtained using the same method and laboratory.
Follow the instructions for the complete order. Many antibody tests and blood counts require no fasting; the linked CMP lists fasting as preferred rather than required. Urine testing requires the specified collection method. Tell the clinician about menstruation, urinary symptoms, recent strenuous exercise, illness, and medications that may affect interpretation. Do not stop prescribed medication on your own.
Ulta Lab Tests offers online access to individual laboratory tests where available. Review current prices and preparation requirements, select the tests agreed with your clinician, and use the collection location specified for your order. Eligible orders may use participating Quest Diagnostics locations. Insurance is not required, HSA/FSA payment may be available, and results can be accessed securely online. See how direct-access laboratory testing works for the ordering process.
Before testing, ask who will review the results, what change would prompt a call, and whether an existing order already includes the same measurement. Direct-access testing supports care; it does not establish a lupus diagnosis.
No. A positive ANA means antinuclear antibodies were detected. These antibodies can occur with lupus, other conditions, certain medications, and in people without an autoimmune disease. The reason testing was ordered, symptoms, examination, and other findings determine what the result means. A positive result alone is insufficient for a lupus diagnosis.
A negative ANA makes SLE less likely, but a clinician must consider the entire presentation and testing method. Persistent, specific clinical findings may justify specialist evaluation. Repeated ANA testing without a change in clinical circumstances is usually less useful than reviewing the original report, symptoms, and possible alternative explanations.
They answer partly different questions. Anti-dsDNA may support diagnosis and, for some people, help assess activity over time. Anti-Smith can provide specific support for SLE in the appropriate setting, but it is not a routine activity marker. Neither test is positive in every person with lupus, so neither can exclude SLE alone.
Blood creatinine and urine testing measure different aspects of kidney health. Protein leakage or abnormal urine sediment may appear before filtration changes enough to raise creatinine. A normal blood result therefore does not replace urinalysis or appropriate urine protein measurement, particularly when lupus is suspected or already diagnosed.
No. Low C3 or C4 can support concern about immune activity, but the significance depends on baseline levels, symptoms, medications, and other laboratory findings. Complement results may remain low in some people and can have explanations besides lupus. Clinicians look for a meaningful pattern rather than treating one low number as proof.
Usually, these are not the main tests used to follow disease activity. Repeating them routinely may add little once the clinical question has been answered. Monitoring more often focuses on symptoms, examination, blood counts, kidney and urine findings, and selected anti-dsDNA and complement trends, according to the person’s disease and treatment.
Yes. Fatigue and anemia have several possible causes, including iron deficiency, bleeding, medication effects, infection, and chronic inflammation. A CBC identifies blood-cell abnormalities but does not establish their cause. Follow-up should be targeted to the blood-count pattern and history rather than assuming that fatigue or a low hemoglobin level means active lupus.
Laboratory access can support an agreed evaluation or monitoring plan, but it cannot replace clinical assessment. A rheumatologist or other treating clinician interprets the results and decides whether further testing or treatment is needed. Discuss the purpose and timing of each test before ordering, and arrange how abnormal results will be reviewed.
The value of lupus testing comes from connecting results to a clinical question. Review your existing reports with your clinician, agree on the next useful measurements, and use the linked Ulta Lab Tests pages to review test details and preparation requirements.
New severe chest pain, difficulty breathing, or neurological symptoms require urgent medical evaluation. New swelling, visible blood in urine, or substantially reduced urine output also warrants prompt medical attention.
Systemic lupus erythematosus is an autoimmune disease that may affect several organs. Its evaluation combines clinical findings with selected antibody, complement, blood-cell, kidney, and urine measurements.
Related tests: ANA, anti-dsDNA, anti-Smith, C3/C4, CBC, CMP, urinalysis, and urine protein-to-creatinine ratio.
Ulta Lab Tests provides access to laboratory testing that can support a clinician-directed evaluation.
This information is educational and is not a substitute for diagnosis, treatment, or individualized medical advice.
Originally published: August 7, 2026 | Updated: September 20, 2026
| Category | Tests with embedded links |
|---|---|
| Core antibody evaluation | ANA with reflex to titer and pattern; anti-dsDNA; anti-Smith |
| Immune activity and blood cells | Complement C3 and C4; CBC with differential and platelets |
| Conditional inflammatory context | ESR; CRP |
| Kidney, urine, and chemistry assessment | Comprehensive metabolic panel; complete urinalysis; urine total protein with creatinine—UPCR |
| Antiphospholipid assessment | Lupus anticoagulant evaluation; cardiolipin IgG/IgM antibodies; beta-2 glycoprotein I antibodies |
| Conditional overlap evaluation | SSA/Ro and SSB/La antibodies; RNP antibody |
| Conditional anemia investigation | Ferritin |
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
